Press Releases 2025 2024 2023 2022 2021 2020 2019 all May 25, 2023 Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 May 17, 2023 Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting May 11, 2023 Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights May 3, 2023 Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference May 2, 2023 Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS March 23, 2023 Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy March 20, 2023 Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference March 7, 2023 Dyne Therapeutics to Present at Upcoming Investor Conferences March 2, 2023 Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights January 3, 2023 Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference November 3, 2022 Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 2, 2022 Dyne Therapeutics to Present at Investor Conferences in November October 31, 2022 Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy October 11, 2022 Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress September 27, 2022 Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference September 12, 2022 Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event September 6, 2022 Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference September 6, 2022 Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 September 6, 2022 Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August 29, 2022 Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Next page › Last page » Displaying 41 - 60 of 113
